the pxONE illumination device for optogenetic flow cytometry was developed at the University of Freiburg. Following collaborations within Freiburg, the pxONE is now used in research labs across Europe and North America. It is our pleasure to see more and more research labs benefiting from our technology and coming up with fantastic novel experimental ideas using the pxONE.
"During my PhD with Prof. Michael Reth at the University of Freiburg, I used the optogenetic protein Dronpa to regulate B lymphocyte activity. At the time being the only person in our lab working with optogenetics, we had zero established methods to analyse our cellular systems. After spending weeks in the dark room at the microscope I was majorly frustrated by the small number of cells one can analyze at once. This led me to develop an illumination device that combines optogentics with flow cytometry, enabling the analysis of 30.000 cells/second (Brenker et al., 2016, JoVE) "
Dr. Kathrin Brenker
(Founder and CEO of opto biolabs)
"I have been using the pxONE with our Miltenyi MACS Quant Analyzer 10 for several years now and we generated key data for our most recent paper on our opto-ligand-TCR system (Yousefi et al., 2019, eLIFE) using the device. On the one hand, the software allows me to illuminate our cells for very short amounts of time (ms). On the other hand, I am also trying out long-time experiments where I measure cells for about 1 hour. Opto Biolabs build a special illumination device for me that illuminates up to 4 ml of cell sample in my FACS tube homogeneously."
Dr. Omid Sascha Yousefi
(Department of Molecular Immunology, Albert-Ludwigs-University Freiburg, Freiburg)
"We measured changes in Ca2+ levels using fluorescent dyes in a reporter HEK cell line to determine the activity of optogenetic tools upon light stimulation. With the pxONE system (red/far red and blue LEDs), we were able to stimulate these tools at specific time points and follow the kinetics of the signal with single cell resolution."
(Institute of Innate Immunity, University of Bonn, Germany)
"I work on the characterization of Staphylococcus aureus skin infection using a new in vivo proliferation biosensor (Seiß et al., 2019, Sci Rep.). To dissect the interplay between neutrophil effector functions and the S. aureus proliferation in real time, I am using the pxONE."
Dr. Elena Seiß
(Institue of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Germany)
“As a synthetic immunology lab dedicated to the invention of innovative optogenetic devices tailored for immunomodulation and gene expression, we are so thrilled to see the pxONE product coming from OptoBioLabs, which enables seamless integration with highthroughput FACS analysis. With the pxONE illumination device, we had the luxury to perform highthroughput screening of our constructs in cells of the immune system with a simple flash of light! Nothing else would be more efficient and simpler!”
Prof. Dr. Yubin Zhou
(Center for Translational Cancer Research, Texas A&M University, USA)
on the image we see Nhung Nguyen and Anh Vo from Yubin Zhou's group using the pxONE with a BD LSRII
Frederic Larbret from the University of Nice Sophia Antipolis is using hte pxONE on a CYTEK Aurora. He uses spectral cytometry to analyze FRET signals in combination with the optogenetic protein DRONPA.
(University of Nice Sophia Antipolis, Nice, France)
"The pxONE device is a great tool for my project because it allows us to determine the kinetics of our optogenetic construct in real time. The ease of changing the light intensity and light duration on the pxONE is an important aspect in determining the kinetics. Being able to photoactivate our construct while simultaneously performing flow cytometry is quite powerful because we can collect data from many cells very quickly and is essential to confirm our optogenetic construct is functioning as expected."
(Pathology Department, University of Rochester School of Medicine and Dentistry, USA)
Prof. Klaus Groschner and his team from the University of Graz study the photophamacological control of TRPC3/6 in T-lymphocytes. They achieve this by analyzing novel reporter for TRPC activity (R/K-GECO fusion proteins) and their recently developed benzimidazole actuators (OptoBI-1) of TRCP3. This precise regulation of T cell activity bears high potential for therapeutic strategies.
(Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University Graz, Austria)